959996-08-8Relevant academic research and scientific papers
Hydrogenation of β-N-substituted enaminoesters in the presence of ruthenium catalysts
Hebbache, Hania,Jerphagnon, Thomas,Hank, Zakia,Bruneau, Christian,Renaud, Jean-Luc
experimental part, p. 870 - 874 (2010/06/16)
β-Aminoesters were prepared in two simple steps from β-ketoesters derivatives and primary amines under mild conditions. Their hydrogenation was performed at 50 °C in the presence of several organometallic catalysts under acidic conditions. The new β-N-substituted aminoesters were isolated in moderate to good yields.
Hydrogenation of β-N-substituted and β-N,N-disubstituted enamino esters in the presence of iridium(I) catalyst
Hebbache, Hania,Hank, Zakia,Bruneau, Christian,Renaud, Jean-Luc
experimental part, p. 2627 - 2633 (2009/12/06)
Several new β-amino esters were prepared in two simple steps from β-keto ester derivatives and primary and secondary amines under mild conditions. The hydrogenation of various enamino esters was performed at 50°C in the presence of iridium catalysts. The new β-N-substituted amino esters were isolated in high yields. Georg Thieme Verlag Stuttgart.
Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
-
Page/Page column 73; 74, (2008/06/13)
The invention provides compounds of formula I: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.
